From Clinical Evidence to Reimbursement: What Biotechnology Companies Need to Plan Before Launch

By Ron Lanton III, Esq. | Lanton Strategies International B.V.

A successful clinical trial does not guarantee that a new medicine will achieve commercial success. Regulatory approval allows a company to bring a treatment to market, but reimbursement determines whether healthcare systems can afford to provide it and whether patients can realistically obtain it.

For biotechnology companies preparing to launch in the United States or Europe, reimbursement planning should begin well before regulatory approval. Decisions about clinical evidence, pricing, payer negotiations, and commercial agreements can affect the financial performance of a product long after development is complete.

Health economics and outcomes research (HEOR) plays an important role in those decisions. It helps manufacturers demonstrate how a treatment compares with existing care, what benefits it provides to patients, and whether those benefits justify its cost.

For smaller biotechnology companies, the challenge is often determining what evidence payers will require and how to incorporate those requirements into development and commercialization plans.

Clinical Approval and Reimbursement Are Different Decisions

Regulators and payers evaluate medicines for different purposes.

Regulatory authorities assess whether a treatment meets applicable standards for safety and effectiveness. Payers and health technology assessment bodies must also consider how the treatment compares with available alternatives, its expected use in clinical practice, and its financial impact on healthcare budgets.

A medicine may demonstrate substantial clinical benefit but still encounter reimbursement restrictions if the available evidence does not adequately address those considerations.

Companies developing oncology drugs, rare disease therapies, and advanced treatments may face particular difficulties when clinical trials involve small patient populations, limited comparative data, or uncertainty about long-term outcomes.

These limitations do not necessarily prevent commercialization. They can, however, affect pricing negotiations, coverage decisions, and the additional evidence manufacturers may be asked to provide after launch.

Management should understand these requirements while clinical development and financing decisions are still being made.

Different Markets Require Different Evidence

European and American reimbursement systems approach these decisions differently.

In the European Union, the Health Technology Assessment Regulation introduced joint clinical assessments in January 2025 for new oncology medicines and advanced therapy medicinal products. The assessments examine comparative clinical evidence, while individual member states retain responsibility for national pricing and reimbursement decisions.

This requires manufacturers to consider both the evidence needed for European clinical assessment and the additional economic information that individual countries may request.

In the United States, coverage decisions vary among Medicare, Medicaid, and commercial insurers. Manufacturers may need to address formulary placement, prior authorization requirements, provider reimbursement, and the financial consequences of treatment administration.

CMS's Cell and Gene Therapy Access Model provides an example of how reimbursement arrangements are changing. The model allows participating state Medicaid programs to use negotiated outcomes-based agreements for certain gene therapies, linking manufacturer payments to patient outcomes.

In October 2026, CMS announced plans to broaden the model beyond its initial focus on sickle cell disease.

For developers of high-cost treatments, these arrangements require consideration of how outcomes will be measured, how information will be collected, and what happens when a patient does not achieve the expected clinical result.

Commercial Agreements Need to Support the Reimbursement Strategy

HEOR and market access planning also affect the contracts a biotechnology company negotiates.

Research agreements may need to address ownership of data, access to patient information, publication rights, and the use of real-world evidence. Licensing and commercialization agreements may allocate responsibility for reimbursement submissions, post-launch studies, and interactions with payers.

Outcomes-based reimbursement arrangements introduce additional contractual obligations. The parties must agree on measurable outcomes, reporting periods, payment adjustments, data responsibilities, and procedures for resolving disputes.

These terms can have significant financial consequences, particularly for smaller biotechnology companies that depend on milestone payments, licensing revenue, or commercial partnerships.

Companies should also consider how reimbursement assumptions affect financial forecasts. A projected launch price may have limited commercial value if coverage restrictions reduce the number of eligible patients or if the costs of administering a treatment make providers reluctant to offer it.

Those issues belong in business development and investment discussions, not solely in the market access department.

Planning Before Launch

Biotechnology executives preparing for commercialization should understand what evidence their target markets will require, how reimbursement decisions could affect patient access, and whether their commercial agreements adequately address those requirements.

That planning may involve HEOR specialists, clinical development teams, legal counsel, reimbursement advisers, and business development executives. Their responsibilities differ, but their work needs to support the same commercial plan.

For companies entering multiple markets, reimbursement assumptions should also account for differences in national payment systems, comparative evidence requirements, and contracting practices.

Clinical success remains essential. Commercial success also requires a realistic understanding of who will pay for the treatment, under what conditions, and whether the resulting reimbursement will support the business.

Companies that address those issues before launch will be better prepared to negotiate with payers, evaluate partnerships, and make informed investment decisions.

This article is provided for general informational purposes and does not constitute legal or regulatory advice.